Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

The researchers found that the withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Lower use of other heart failure medications ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure in the EU, fulfilling a key 2025 pipeline objective. The pharma group ...

There are over six million Americans with heart failure who are at greater risk of losing their cognitive abilities earlier in life, a study suggests.

“Our results show that heart failure medications continue to provide ... the current recommendation to continue with RASi/ARNi and MRA treatment, but also opens up the possibility of ...

Heart failure is a serious, chronic condition. While medication can help the heart recover and improve its function, this study suggests that the medications themselves may continue to protect the ...

Chronic kidney disease (CKD) has diverse etiologies and complex pathogenesis, and is prone to recurrent episodes and prolonged illness. In recent years, the prevalence of CKD has been increasing year ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...